Abivax (AAVXF) Total Liabilities (2021 - 2025)

Abivax has reported Total Liabilities over the past 5 years, most recently at $81.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $81.1 million for Q4 2025, up 68.83% from a year ago — trailing twelve months through Dec 2025 was $81.1 million (up 68.83% YoY), and the annual figure for FY2025 was $78.7 million, up 61.79%.
  • Total Liabilities for Q4 2025 was $81.1 million at Abivax, up from $48.0 million in the prior quarter.
  • Over the last five years, Total Liabilities for AAVXF hit a ceiling of $91.7 million in Q4 2021 and a floor of $40.2 million in Q4 2023.
  • Median Total Liabilities over the past 5 years was $66.6 million (2022), compared with a mean of $65.5 million.
  • Biggest five-year swings in Total Liabilities: crashed 39.66% in 2023 and later soared 68.83% in 2025.
  • Abivax's Total Liabilities stood at $91.7 million in 2021, then fell by 27.36% to $66.6 million in 2022, then plummeted by 39.66% to $40.2 million in 2023, then rose by 19.49% to $48.0 million in 2024, then soared by 68.83% to $81.1 million in 2025.
  • The last three reported values for Total Liabilities were $81.1 million (Q4 2025), $48.0 million (Q4 2024), and $40.2 million (Q4 2023) per Business Quant data.